NeoImmuneTech Tech Stack

NeoImmuneTech uses 8 technology products and services including Amazon Web Services, Twemoji, Google Fonts API, and more. Explore NeoImmuneTech's tech stack below.

Amazon Web Services

Cloud Hosting

Twemoji

Font Scripts

Google Fonts API

Font Scripts

React

Javascript Frameworks

dc.js

Javascript Graphics

Google Code Prettify

Miscellaneous

Animate.css

UI Frameworks

prettyPhoto

Web Tools And Plugins

NeoImmuneTech Email Formats	Example	Percentage
FLast@neoimmunetech.com	JDoe@neoimmunetech.com	78%
FMLast@neoimmunetech.com	JMDoe@neoimmunetech.com	11%
LastF@neoimmunetech.com	DoeJ@neoimmunetech.com	9%
Last@neoimmunetech.com	Doe@neoimmunetech.com	2%

NeoImmuneTech Email Formats

Example

Percentage

FLast@neoimmunetech.com

JDoe@neoimmunetech.com

78%

FMLast@neoimmunetech.com

JMDoe@neoimmunetech.com

11%

LastF@neoimmunetech.com

DoeJ@neoimmunetech.com

Last@neoimmunetech.com

Doe@neoimmunetech.com

Frequently Asked Questions

Where is NeoImmuneTech's headquarters located?

NeoImmuneTech's main headquarters is located at 2400 Research Boulevard Suite 250 Rockville, Maryland 20850 United States. The company has employees across 2 continents, including North AmericaEurope.

What is NeoImmuneTech's stock symbol?

NeoImmuneTech is a publicly traded company; the company's stock symbol is 950220.KQ.

What is NeoImmuneTech's official website and social media links?

NeoImmuneTech's official website is neoimmunetech.com and has social profiles on LinkedIn Crunchbase.

What is NeoImmuneTech's SIC code NAICS code?

NeoImmuneTech's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does NeoImmuneTech have currently?

As of February 2026, NeoImmuneTech has approximately 39 employees across 2 continents, including North AmericaEurope. Key team members include Chief Executive Officer: L. O.Executive Vice President & Chief Medical Officer: N. D. L.Senior Director, Head Of Clinical Operations Division: A. O.. Explore NeoImmuneTech's employee directory with LeadIQ.

What industry does NeoImmuneTech belong to?

NeoImmuneTech operates in the Biotechnology Research industry.

What technology does NeoImmuneTech use?

NeoImmuneTech's tech stack includes Amazon Web ServicesTwemojiGoogle Fonts APIReactdc.jsGoogle Code PrettifyAnimate.cssprettyPhoto.

What is NeoImmuneTech's email format?

NeoImmuneTech's email format typically follows the pattern of FLast@neoimmunetech.com. Find more NeoImmuneTech email formats with LeadIQ.

When was NeoImmuneTech founded?

NeoImmuneTech was founded in 2014.

NeoImmuneTech

Q: What is NeoImmuneTech's official website and social media links?

NeoImmuneTech's official website is neoimmunetech.com. NeoImmuneTech has social profiles on LinkedIn.

Q: How many employees does NeoImmuneTech have currently?

NeoImmuneTech has approximately 39 employees.

Q: What technology does NeoImmuneTech use?

NeoImmuneTech's tech stack includes Webpack, dc.js, Twemoji, Google Analytics, WordPress.

Biotechnology ResearchMaryland, United States11-50 Employees

NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. 

Our lead drug candidate, NT-I7, is the only clinical-stage long acting rhIL-7, and is uniquely positioned to address unmet medical needs in Immuno-Oncology and Infectious Diseases. IL-7 is a fundamental cytokine for lymphocyte development, survival, and memory development. Furthermore, NT-I7 has been shown clinically to have desired PK/PD and safety profiles, making it an ideal combination partner with T-cell targeted therapies. 

NT-I7 is being studied in multiple clinical trials and many in collaboration with industry leaders in I-O, including Merck and Roche for CPI combination trials.

Follow us on X @neoimmunetech

Insights

Similar companies to NeoImmuneTech

Immatics

GammaDelta Therapeutics

Indapta Therapeutics

Immunocore

AlloVir

NeoImmuneTech Tech Stack

Media & News

NeoImmuneTech, Inc. hires Luke Oh as President and Chief Executive Officer.

NeoImmuneTech, Inc. partners with Imugene Limited.

NeoImmuneTech, Inc. is developing next-gen cancer therapy.

NeoImmuneTech, Inc. launches biomarker analysis of the immune-associated changes in the tumor microenvironment.

NeoImmuneTech, Inc. is developing NT-I7 as a T cell amplifier immunotherapy.

NeoImmuneTech, Inc. hired Jean Fan as Chief Clinical Officer on Aug 25th '21.

NeoImmuneTech, Inc. launched Clinical Trial Application on Jun 29th '21.

NeoImmuneTech's Email Address Formats